Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365018 | 0.91 | MAPT (0.58) | RAB9ANPC1MAPTCASRSMN1; SMN2 | |
| SCHEMBL5681280 | 0.89 | ITGB1 (0.54) | RAB9ANPC1MAPTSMN1; SMN2ITGB1 | |
| SCHEMBL5865365 | 0.89 | ITGB1 (0.54) | RAB9ANPC1MAPTSMN1; SMN2ITGB1 | |
| SCHEMBL5679358 | 0.83 | SMN1; SMN2 (0.60) | RAB9ANPC1MAPTCASRSMN1; SMN2 | |
| SCHEMBL5679325 | 0.83 | SMN1; SMN2 (0.70) | RAB9ANPC1MAPTCASRSMN1; SMN2 | |
| SCHEMBL1019967 | 0.76 | SMN1; SMN2 (0.78) | RAB9ANPC1MAPTCASRSMN1; SMN2 | |
| SCHEMBL7655911 | 0.75 | SMN1; SMN2 (0.66) | RAB9ANPC1MAPTCASRSMN1; SMN2 | |
| SCHEMBL2001988 | 0.74 | RAB9A (0.57) | RAB9ANPC1MAPTCASRSMN1; SMN2 | |
| SCHEMBL4915540 | 0.73 | NPC1 (0.76) | RAB9ANPC1MAPTSMN1; SMN2NAMPT | |
| SCHEMBL4122902 | 0.73 | TRPV1 (0.65) | RAB9ANPC1MAPTSMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064229-B2 | ethyl 4-[(4-[[2-methyl-phenyl)amino]carbonyl]amino)phenyl]amino]-4-oxo-2-phenyl-butanoyl)amino]benzoate for treatment of inflammatory diseases and conditions mediated by integrins (atherosclerosis, asthma, obstructive pulmonary disease, allergies, diabetes, multiple sclerosis, and autoimmune disorders) | BAYER HEALTHCARE AG (DE) | 2006-06-20 | — | — | US | disclosed |
| EP-1406865-B1 | SUCCINIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20040254157-A1 | Succinic acid derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1406865-A2 | SUCCINIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004460-A2 | SUCCINIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004460-A2 | SUCCINIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254157-A1 | Succinic acid derivatives | SUCNR1, SDHA, SDHB | RAB9A 2327/4885NPC1 2510/4885MAPT 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.